Rhythm Pharma Sees 5% Q1 Sales Growth to $60.1M, Wins EU Nod, Targets Japan H2
RYTM•Rhythm Pharmaceuticals reported $60.1 million in global IMCIVREE sales in Q1 2026, up 5% from Q4 with $36.9 million U.S. revenue and $23.2 million overseas. The company logged over 150 U.S. patient starts post-FDA approval, secured European approval for acquired hypothalamic obesity, and targets a Japanese launch in H2 2026.
1. Q1 Financial Results
Rhythm Pharmaceuticals reported first quarter 2026 net product revenue of $60.1 million from global IMCIVREE sales, marking a 5% sequential increase over Q4 2025. U.S. revenue accounted for $36.9 million, while international sales rose 27% to $23.2 million driven by expanded reimbursement and inventory recovery.
2. Regulatory Milestones
Regulatory achievements include FDA approval of IMCIVREE for acquired hypothalamic obesity on March 19, 2026, and European Commission marketing authorization granted on May 1, 2026. The Japanese New Drug Application has been accepted and is under PMDA review, with a potential launch targeted for the second half of 2026.
3. Commercial and Pipeline Advances
Rhythm recorded over 150 U.S. IMCIVREE patient starts within six weeks of FDA approval, reinforcing early launch uptake. Positive BMI data from pediatric acquired HO patients were presented, and the company anticipates Q2 Prader-Willi syndrome results and mid-year RM-718 trial readouts.
